Medtronic and BioIntelliSense Collaborate for Exclusive U.S. Distribution of BioButton Wearable

Medtronic and BioIntelliSense have established a strategic partnership for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton®, the multi-parameter wearable that can measure up to 1,440 vital sign measurements per day. It has the potential to enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge.

The terms of the deal were not disclosed.

With the partnership, the Medtronic Patient Monitoring business can offer access to a medical-grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge.